Basel, Switzerland, 04 Sep 2014 – To help address the growing costs and long development timelines facing vaccine manufacturers, Lonza is announcing the launch of the Vaccine Design and Development Services Platform. This platform includes in silico and in vitro tools to accelerate the design and assessment of vaccine candidates for their ability to provoke an effective immune response. Allowing companies to focus on the most promising vaccine candidates early in the process can help reduce time and costs, maximizing R&D resources.
Lonza is uniquely positioned to offer customers these services that include our Epibase™ In Silico (IS) and In Vitro (IV) tools for immunogenicity assessment. Epibase™ IS is a predictive tool driven by structural bioinformatics in conjunction with experimental data. This tool can predict potential peptide/HLA binding, which can be used to rationally design an efficacious vaccine. Recent enhancements enable extensive prediction of both HLA Class I CD8+ and ...
